[go: up one dir, main page]

GT201100127A - Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 - Google Patents

Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1

Info

Publication number
GT201100127A
GT201100127A GT201100127A GT201100127A GT201100127A GT 201100127 A GT201100127 A GT 201100127A GT 201100127 A GT201100127 A GT 201100127A GT 201100127 A GT201100127 A GT 201100127A GT 201100127 A GT201100127 A GT 201100127A
Authority
GT
Guatemala
Prior art keywords
benzoquinazolinona
aril
methyl
modulators
receiver
Prior art date
Application number
GT201100127A
Other languages
English (en)
Inventor
Scott D Kuduk
Douglas C Beshore
Di Marco Christina Ng
Thomas J Greshock
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201100127A publication Critical patent/GT201100127A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/19—Acids containing three or more carbon atoms
    • C07C53/21—Acids containing three or more carbon atoms containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

EL INVENTO SE REFIERE A UNA CLASE DE COMPUESTOS DE ARIL METIL BENZOQUINAZOLINONA, SUS SALES, COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN Y SU USO EN TERAPIA DEL CUERPO HUMANO. EN PARTICULAR, SE REFIERE A UNA CLASE DE COMPUESTOS DE BENZOQUINAZOLINONA LOS CUALES SON MODULADORES ALOSTÉRICOS POSITIVOS DEL RECEPTOR M1 MUSCARÍNICO, Y POR LO TANTO SON ÚTILES EN EL TRATAMIENTO DE LA ENFERMEDAD DE ALZHEIMER Y OTRAS ENFERMEDADES MEDIADAS POR EL RECEPTOR M1 MUSCARÍNICO.
GT201100127A 2008-11-20 2011-05-17 Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1 GT201100127A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US19974008P 2008-11-20 2008-11-20

Publications (1)

Publication Number Publication Date
GT201100127A true GT201100127A (es) 2014-02-10

Family

ID=41565956

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201100127A GT201100127A (es) 2008-11-20 2011-05-17 Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1

Country Status (36)

Country Link
US (4) US8557832B2 (es)
EP (1) EP2358686B1 (es)
JP (1) JP5102397B2 (es)
KR (1) KR101305590B1 (es)
CN (1) CN102292323B (es)
BR (1) BRPI0921924A2 (es)
CA (1) CA2743562C (es)
CO (1) CO6361928A2 (es)
CR (1) CR20110268A (es)
CY (1) CY1113665T1 (es)
DK (1) DK2358686T3 (es)
DO (1) DOP2011000135A (es)
EA (1) EA019098B1 (es)
EC (1) ECSP11011066A (es)
ES (1) ES2393694T3 (es)
GE (1) GEP20156348B (es)
GT (1) GT201100127A (es)
HN (1) HN2011001358A (es)
HR (1) HRP20120992T1 (es)
IL (1) IL212573A (es)
MA (1) MA32898B1 (es)
MX (1) MX2011005284A (es)
MY (1) MY162502A (es)
NI (1) NI201100100A (es)
NZ (1) NZ592961A (es)
PE (1) PE20120031A1 (es)
PL (1) PL2358686T3 (es)
PT (1) PT2358686E (es)
RS (1) RS52528B (es)
SG (1) SG171769A1 (es)
SI (1) SI2358686T1 (es)
SV (1) SV2011003912A (es)
TN (1) TN2011000209A1 (es)
UA (1) UA100459C2 (es)
WO (1) WO2010059773A1 (es)
ZA (1) ZA201103612B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2473048B1 (en) * 2009-08-31 2015-03-25 Merck Sharp & Dohme Corp. Pyranyl aryl methyl benzoquinazolinone m1 receptor positive allosteric modulators
WO2011049731A1 (en) 2009-10-21 2011-04-28 Merck Sharp & Dohme Corp. Quinolinone-pyrazolone m1 receptor positive allosteric modulators
WO2011075371A1 (en) * 2009-12-14 2011-06-23 Merck Sharp & Dohme Corp. Pyridoquinazolinone m1 receptor positive allosteric modulators
ME02421B (me) 2009-12-17 2016-09-20 Merck Sharp & Dohme Pozitivni alosterni modulatori m1 receptora na bazi hinolin amida
US8383638B2 (en) * 2009-12-21 2013-02-26 Merck Sharp & Dohme Aminobenzoquinazolinone M1 receptor positive allosteric modulators
WO2011159553A1 (en) * 2010-06-15 2011-12-22 Merck Sharp & Dohme Corp. Heterocyclic fused phenanthrolinone m1 receptor positive allosteric modulators
US8697690B2 (en) 2010-07-01 2014-04-15 Merck Sharp & Dohme Corp. Isoindolone M1 receptor positive allosteric modulators
EP2624697B1 (en) * 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators
US9284312B2 (en) 2011-05-17 2016-03-15 Merck Sharp & Dohme Corp. N-methyl tetrahydroquinoline M1 receptor positive allosteric modulators
KR20140051403A (ko) 2011-08-12 2014-04-30 바스프 에스이 안트라닐아미드 화합물 및 살충제로서의 그의 용도
EA201400214A1 (ru) 2011-08-12 2014-07-30 Басф Се Антраниламидные соединения и их применение в качестве пестицидов
WO2013097052A1 (en) 2011-12-30 2013-07-04 Abbott Laboratories Bromodomain inhibitors
US9233911B2 (en) 2012-01-10 2016-01-12 Council Of Scientific & Industrial Research Cu-mediated annulation for the production of 1-amino-2-naphthalenecarboxylic acid derivatives
WO2013129622A1 (ja) 2012-03-02 2013-09-06 武田薬品工業株式会社 複素環化合物およびその用途
WO2014077401A1 (ja) 2012-11-19 2014-05-22 武田薬品工業株式会社 含窒素複素環化合物
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
CN106232572B (zh) * 2014-04-17 2018-11-13 住友化学株式会社 硝基化合物的制造方法
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination
TN2017000508A1 (en) * 2015-06-26 2019-04-12 Takeda Pharmaceuticals Co 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic m1 receptor
US20180250270A1 (en) 2015-09-11 2018-09-06 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
WO2017058689A1 (en) * 2015-09-30 2017-04-06 Merck Sharp & Dohme Corp. Crystal forms of a m1 receptor positive allosteric modulator
EP3356332A4 (en) 2015-09-30 2019-06-19 Merck Sharp & Dohme Corp. METHOD FOR PRODUCING POSITIVE ALLOSTERIC M1 RECEPTOR MODULATORS
JP6787913B2 (ja) * 2015-10-20 2020-11-18 武田薬品工業株式会社 複素環化合物
CA3018802A1 (en) 2016-04-15 2017-10-19 Abbvie Inc. Bromodomain inhibitors
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
BR112019007468B1 (pt) * 2016-10-14 2023-02-14 Pi Industries Ltd Derivados da fenilamina 4-substituídos e seu uso para proteger as culturas combatendo microrganismos fitopatogênicos indesejáveis
WO2018083051A1 (en) 2016-11-01 2018-05-11 F. Hoffmann-La Roche Ag 1,3-dihydro-1,4-benzodiazepine-2-thiones for the treatment of cns related diseases
US12298319B2 (en) 2017-05-19 2025-05-13 Takeda Pharmaceutical Company Limited Method for measuring alpha value of muscarinic M1 receptor positive allosteric modulators
US12012419B2 (en) 2018-09-28 2024-06-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN117043302A (zh) 2021-03-18 2023-11-10 默克专利有限公司 用于有机电致发光器件的杂芳族化合物
EP4447953A1 (en) 2021-12-13 2024-10-23 Sage Therapeutics, Inc. Combination of muscarinic receptor positive modulators and nmda positive allosteric modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL326083A1 (en) * 1995-10-02 1998-08-17 Hoffmann La Roche Novel pyrimidin derivatives as antagonists of 5ht 2c receptor
JP2001507349A (ja) * 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
KR100607634B1 (ko) * 1998-10-16 2006-08-02 다이닛본 스미토모 세이야꾸 가부시끼가이샤 퀴나졸리논 유도체
JP2005089298A (ja) * 2001-09-18 2005-04-07 Japan Tobacco Inc ナフタレン化合物及びその医薬用途
WO2004073639A2 (en) * 2003-02-19 2004-09-02 Merck & Co. Inc. Treatment of psychosis with a muscarinic m1 receptor ectopic activator
WO2006117305A1 (en) * 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag (3,4-dihydro-quinazolin-2-yl)-(2-aryloxy-ethyl)-amines having an activity on the 5-ht receptor
ATE530544T1 (de) 2006-06-28 2011-11-15 Merck Sharp & Dohme Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EP2624697B1 (en) * 2010-10-04 2015-11-25 Merck Sharp & Dohme Corp. Dihydrobenzoquinazolinone m1 receptor positive allosteric modulators

Also Published As

Publication number Publication date
WO2010059773A1 (en) 2010-05-27
US8883810B2 (en) 2014-11-11
CN102292323B (zh) 2014-12-24
US20150031713A1 (en) 2015-01-29
HK1154587A1 (en) 2012-04-27
HRP20120992T1 (hr) 2012-12-31
US20160229813A1 (en) 2016-08-11
US8557832B2 (en) 2013-10-15
PE20120031A1 (es) 2012-02-05
EP2358686B1 (en) 2012-09-26
SI2358686T1 (sl) 2013-05-31
GEP20156348B (en) 2015-08-25
CR20110268A (es) 2011-07-01
NZ592961A (en) 2012-09-28
IL212573A (en) 2015-01-29
MY162502A (en) 2017-06-15
MA32898B1 (fr) 2011-12-01
EP2358686A1 (en) 2011-08-24
HN2011001358A (es) 2014-03-03
UA100459C2 (en) 2012-12-25
CA2743562A1 (en) 2010-05-27
BRPI0921924A2 (pt) 2015-12-29
PT2358686E (pt) 2012-12-06
US20140005182A1 (en) 2014-01-02
SV2011003912A (es) 2011-10-13
KR20110073596A (ko) 2011-06-29
CY1113665T1 (el) 2016-06-22
CA2743562C (en) 2014-03-18
ES2393694T3 (es) 2012-12-27
TN2011000209A1 (en) 2012-12-17
PL2358686T3 (pl) 2013-02-28
US20110224198A1 (en) 2011-09-15
ZA201103612B (en) 2012-01-25
NI201100100A (es) 2011-09-12
DOP2011000135A (es) 2011-07-31
AU2009316578A1 (en) 2011-06-23
US9708273B2 (en) 2017-07-18
CO6361928A2 (es) 2012-01-20
KR101305590B1 (ko) 2013-09-09
RS52528B (sr) 2013-04-30
IL212573A0 (en) 2011-06-30
JP2012509343A (ja) 2012-04-19
DK2358686T3 (da) 2013-01-07
JP5102397B2 (ja) 2012-12-19
EA201170705A1 (ru) 2011-12-30
MX2011005284A (es) 2011-06-17
EA019098B1 (ru) 2014-01-30
ECSP11011066A (es) 2011-06-30
SG171769A1 (en) 2011-07-28
CN102292323A (zh) 2011-12-21

Similar Documents

Publication Publication Date Title
GT201100127A (es) Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1
ECSP12012326A (es) Derivados de aminopirimidina como moduladores de la lrrk2
DOP2011000264A (es) Derivados de aminotetralina, composiciones farmaceuticas que los contienen y sus usos en terapia
MX379530B (es) Compuestos agonistas del receptor muscarínico m4.
CR20130309A (es) Derivados de biciclo [3,2,1] octilamida y sus usos
NI201000005A (es) Agentes citotóxicos que comprenden nuevos derivados de tomaimicina y su uso terapéutico.
GT201200147A (es) Antagonistas de espiro-oxindol de mdm2
CL2011002766A1 (es) Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras.
UY31350A1 (es) (carboxilalquilenfenil)feniloxamidas, procedimiento para su preparación y su utilización como medicamentos
CL2011001658A1 (es) Compuestos derivados de sulfonamidas, moduladores de los canales de sodio; composición farmacéutica que los comprende; y su uso en el tratamiento del dolor.
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
CY1116927T1 (el) Προφαρμακα της τετραϋδροκανναβινολης, συνθεσεις οι οποιες περιλαμβανουν προφαρμακα της τετραϋδροκανναβινολης και μεθοδοι χρησης των ιδιων
DOP2007000016A (es) Agentes citotoxicos que comprenden nuevos derivados de tomaimicina.
PA8720801A1 (es) Nuevas combinaciones terapeuticas para el tratamiento de la depresion
CY1117909T1 (el) Φαρμακευτικη συνθεση που περιλαμβανει ολμεσαρτανη μεδοξομιλη και ροσουβαστατινη ή το αλας της
MX375286B (es) Moduladores de receptores nmda de espiro-lactama y sus usos.
GT201300080A (es) Proceso de elaboracion para derivados de pirimidina
UY33277A (es) Compuestos de anillo espiro-tetraciclico como moduladores de beta-secretasa y métodos de uso
DOP2011000134A (es) Lactamas como inhibidores de beta secretasa
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
CY1118057T1 (el) Φαρμακευτικη συνθεση για στοματικη χορηγηση
CR9722A (es) Derivados de benzilpiperazina y su uso medico
GT200500378A (es) Macrolidos
CR20150266A (es) Formulaciones de liberación modificada para oprozomib
UY29735A1 (es) Piperazinas sustituidas como antagonistas de receptores de glutamato metabotrópicos